Indications
Short-term symptomatic treatment of anxiety in adults when the usual therapeutic measures have failed.
Acute and chronic schizophrenia.
Contraindications
Patients with known hypersensitivity to any component of the formula.
Adrenal marrow tumours.
Acute porphyria.
CNS depression states, coma, alcoholic poisoning, and CNS depressants.
Concomitant prolactin-dependent tumours (e.g. breast cancer, pituitary gland prolactinomas).
Pregnancy (especially during the first 16 weeks of pregnancy) and breastfeeding women.
Compositon/Ingredients
Sulpiride 50mg
Dosage and administration
Short-term symptomatic treatment of anxiety in adults when the usual therapeutic measures have failed: 50 – 150mg daily for a maximum period of 4 weeks.
Schizophrenia:
Patients with negative symptoms: Initial doses of 200 to 400mg twice daily, if necessary increased up to a total of 800mg daily.
Patients with positive symptoms: 400mg of sulpiride twice daily, if necessary increased up to a maximum of 1.2g twice daily. Patients with mixed positive and negative symptoms: 400 to 600mg twice daily.
Elderly patients: Lower initial doses of 50 – 100mg twice daily, subsequently adjusted as required.
Children over 14 years: A daily dose of 3 to 5mg/kg.
Precaution
In the event of renal impairment, reduce the dosage and increase patient monitoring. In the event of severe renal impairment, prescription of intermittent treatment courses is recommended. Monitoring of sulpiride treatment must be increased in epileptic patients, manic or hypomanic patients and the elderly people with dementia. All possible risk factors for venous thromboembolism (VTE) should be identified before and during treatment with antipsychotics and preventative measures undertaken. Gradual withdrawal is advisable because acute withdrawal symptoms (including nausea, vomiting, sweating and insomnia), recurrence of psychotic symptoms and and the emergence of involuntary movement disorders (such as akathisia, dystonia and dyskinesia) may occur after abrupt cessation of drug. Alcohol consumption and use of medicinal products containing alcohol are strongly inadvisable throughout the duration of treatment. Stadpizide 50 must absolutely be discontinued in the event of unexplained hyperthermia. Stadpizide 50 contains lactose and wheat starch. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose – galactose malabsorption and patients with wheat allergy (different from coeliac disease) shouldnot take this medicine. Stadpizide 50 may cause drowsiness which may affect performance of skilled tasks (e.g. driving or operating machinery), especially at start of treatment.
Storage
Store at temperature below 30°C, protect from light.
